Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee
Summary of Main Points from the Meeting held on the 8th September 2014

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the June and July 2014 meeting were approved and will be circulated.

3. Matters Arising

The Committee noted the matters arising from the previous meeting.

4. Formulary Applications

Full applications

- **Tacrolimus 0.5mg, 1mg and 5mg Capsules (Adoport®)**

Decision: Approved

Tacrolimus was approved for steroid resistant or steroid dependent frequently relapsing Nephrotic Syndrome in adults (either minimal change disease or Focal Sclerosing Glomerulosclerosis) - 2nd or 3rd Line. This is an unlicensed but widely recognised indication.

- **Dymista® - Fluticasone & Azelastine Nasal Spray**

Decision: Deferred

- **Imiquimod 3.75% Cream (Zyclara®)**

Decision: Approved (with conditions)

Zyclara® is indicated for the topical treatment of non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunecompetent adults.
Zyclara® was approved for the treatment of AK where the area being treated exceeds >25cm^2 as Aldara® (Currently on the formulary) does not have a license for the treatment of large areas. When treating these larger areas Zyclara® confers additional benefits including reduced clinic time and reduced cost of treatment. The prescribing of Zyclara® will be restricted to consultant prescribing and hospital use. The Dermatology Team have been asked to undertake a 6-month audit (approximately 50 patients) and to feedback the results at a future meeting so that the panel can assess ongoing support for having this drug available on the formulary.

- **Dabrafenib 75mg and 150mg capsules (Tafinlar®)**

Decision: Approved

Approved for prescribing in accordance with the Cancer Drugs Fund approved indication – unresectable or metastatic melanoma with BRAF V600 mutation intolerant to Vemurafenib.

Individual funding requests (For noting only)

- **Tocilizumab IV**

Decision: Noted

Approved by the Pharmacoecomonic Board for the treatment of Progressive Multifocal Leucoencephalopathy.

- **Alitretinoin oral (For noting only)**

Decision: Noted

Approved by the Pharmacoecomonic Board for the treatment of Pityriasis Rubra Pilaris.

- **Rituximab IV (For noting only)**

Decision: Noted

Approved by the Pharmacoecomonic Board for the treatment of Immune Medicated Thrombocytopenia.

Ex panel requests

- **Mefenamic Acid 500mg Tablets**

Decision: Approved

Indicated for the management of menorrhagia
Tablets are more cost effective than capsules which are currently included on the formulary.

- **Alprostadil 3mg/g Cream (Vitaros®)**

Decision: Approved

Indicated for the management of Erectile Dysfunction
Intercavernosal injections (Viridal® / Caverject®) are currently on manufacturer's delay.
Currently using alternative formulation - urethral pellets (MUSE®).
Topical cream will provide a further alternative formulation
Topical cream more cost effective than pellets

Removals

- **Fesoterodine 4mg and 8mg MR Tablets**

Indicated for urinary frequency and urgency
Not included on the NWLIF but usage continues to increase with initiation of new patients in Gynaeurology and Urology.
Plan going forward will be to make Fesoterodine non-formulary but maintain a minimum stock level in Pharmacy for continued supplies for patients already initiated on it.

5. Trust Medicines Policy

- **Trust Medicines Policy: Section 4 - Safe storage of medicines**

Decision: Approved

Scheduled review with minor amendments including: Use of access code panels on wards/departments, Job title changes and inclusion of freezer temperature monitoring on wards/departments.

- **Trust Medicines Policy: Section 6 - Controlled Drugs**

Decision: Approved
Updated to include Growth Hormone being a Schedule 4 Controlled Drug.

6. Medicines Management

- **Proposal for snacks to be added to Lastword EPR**

Decision: Rejected
This proposal received from the dieticians involves a request to include "Snacks" on Lastword EPR similar to how drugs are listed. This has been proposed as it has been noted by the dieticians that snacks are not always being issued to patients who require them (patients who cannot meet their estimated nutritional requirements from their hospital meals alone). There is currently no robust mechanism in place that provides feedback to the dieticians when snacks have not been issued or have been declined by patients.
This proposal was discussed and the general consensus is that this may increase the risk of missed drug doses due to increased drug traffic on the Lastword EPR drug administration screens.

7. NICE TA Guidance

TA314 - Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure
Implantable cardioverter defibrillators are recommended as a possible treatment for people who have had a serious ventricular arrhythmia, who have an inherited heart condition linked to a high risk of sudden death, or who have had surgery to repair congenital heart disease.Implantable cardioverter defibrillators, and cardiac resynchronisation therapy with defibrillation or pacing, are recommended as possible treatments for certain people with heart failure because of left ventricular dysfunction.
Action: No action - Does not affect Formulary

TA315 - Canagliflozin in combination therapy for treating Type 2 Diabetes
If a person needs to take 2 antidiabetic drugs, canagliflozin is recommended as a possible treatment for people with type 2 diabetes when taken with a drug called metformin, only if the person:

- cannot take a type of drug called a sulfonylurea or
- is at significant risk of hypoglycaemia or its consequences

If a person needs to take 3 antidiabetic drugs, canagliflozin is recommended as a possible treatment when taken with either metformin and a sulfonylurea, or metformin and a type of drug called a thiazolidinedione

Canagliflozin is recommended as a possible treatment taken with insulin, with or without other antidiabetic drugs.
Action: Approved via Chair's action for addition to the formulary in July 2014 Application form noted

TA316 - Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen
Enzalutamide is recommended as a possible treatment option for adults with metastatic hormone-relapsed prostate cancer, who have already had treatment with docetaxel-containing chemotherapy
Action: Currently included on the formulary. Update formulary to indicate that Enzalutamide is now used in line with NICE TA316.

TA317 - Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Prasugrel 10 mg is recommended as a possible treatment for adults with acute coronary syndrome who are having percutaneous coronary intervention
Action: Currently included on the formulary. Update formulary to indicate that Prasugrel is now used in line with NICE TA317.

TA318 - Lubiprostone for treating chronic idiopathic constipation)
Lubiprostone is recommended as an option for treating chronic idiopathic constipation, that is, for adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered
Action: To be added to the formulary. Application form pending - Will be noted at the October meeting).

TA319 - Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab is recommended as a possible treatment for adults with advanced (unresectable or metastatic) melanoma that has not been treated before.
Action: Currently included on formulary. Update formulary to indicate that Ipilimumab is now used in line with NICE TA319.

8. IVIG Update

There were 16 IVIG issues in June 2014, with 6 new requests:

- One for Toxic Epidermal Necrolysis (TENS) (Red Indication)
- One for Kawasaki Disease (Red Indication)
- One for Myasthenia Gravis (Blue Indication)
- One for CIDP (Red Indication)
- Two for ITP (Red indication)

There were 12 IVIG issues in July 2014, with 5 new requests:

- Two for Guillian Barre (Red Indication)
- One for Kawasaki Disease (Red Indication)

- One for Alloimmune Thrombocytopenia (Foetal maternal) (Red Indication)
- One for Secondary antibody deficiency (Blue Indication)

There were 19 IVIG issues in August 2014, with 6 new requests:

- One for Toxic Epidermal Necrolysis (TENS) (Red Indication)
- Four for ITP (red indication)

One for Haemolytic Disease of the New born (red indication)

9. Items for noting

- **Audit: Medicines Security - November 2013**

Audit of Medicines Security at C&W undertaken in November 2013

- **Audit: Medicines reconciliation at admission - June 2014**

Audit of Medicines reconciliation at admission at C&W undertaken in June 2014

- **Audit: Technical Services Regional Audit and Action plan - June 2014**

Regional Audit undertaken in Pharmacy Technical Services in June 2014 and subsequent action plan

- **NHS England letter re CD Occurrence Report**

Letter from NHS England introducing the new CD Occurrence Report proforma

- **Trust Quarterly CD Report 2014/15 Q1**

Quarterly CD Report 2014/15 Q1

- **Trust Quarterly CD Occurrence Report |(With addendum) 2014/15 Q1**

Quarterly CD Occurrence Report 2014/15 Q1

- **NWL Prescribing and Medicines Management Bulletins - June and August 2014**

Bulletins published by NWL Prescribing and Medicines Management for June and August 2014

- **MHRA Update - May 2014**

MHRA Update for May 2014

- **MHRA Update - June 2014**

MHRA Update for June 2014

- **MHRA Update - July 2014**

MHRA Update for July 2014

- **MHRA Update - August 2014**

MHRA Update for August 2014

10. Meeting minutes for noting

- HIV Drugs Sub-committee meeting - June 2014
- Local Chemotherapy Group meeting - July 2014
- Antibiotic Steering Group meeting - January 2014
- Antibiotic Steering Group meeting - April 2014
- Antibiotic Steering Group meeting - July 2014

12. AOB

Chemotherapy policies approved:

- Policy for the Safe Prescribing, Handling and Administration of Systemic Anti-Cancer Treatment Drugs
- Policy for the safe dispensing, labelling and administration of vinca alkaloids
- Intrathecal Cytotoxic Chemotherapy Policy

13. Date of next meeting

Monday 13th October 2014, 8.00 - 9.00 – Board Room, Lower Ground Floor
Closing date for papers: Friday 19th September 2014